SINGULAIR—The first and only oral
tablet approved for prevention of
EIB in patients aged 15 years
and older.
Learn more about SINGULAIR in EIB.
For adults
- Not well controlled on a short-acting ß-agonist (SABA) 2,3
- Not well controlled on a SABA during the allergy season 4
- Versus an ICS
(beclomethasone) 5
For pediatric and
adolescent patients
- Indicated for treatment of asthma, with an established safety profile, in patients as young as 12 months
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.
Important Information
SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician.
Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.
For prevention of EIB, a single dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.
Patients already taking 1 tablet daily for another indication should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting ß-agonist.
Chronic daily administration of SINGULAIR for other indications has not been established to prevent acute episodes of EIB.
Patients with known aspirin sensitivity should continue avoidance of aspirin or nonsteroidal antiinflammatory agents while taking SINGULAIR.
Safety and effectiveness of SINGULAIR for EIB in patients younger than 15 years have not been established.
Before prescribing SINGULAIR, please read the Prescribing Information.
For general information and other services for physicians
SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck & Co., Inc.